AIMS: To examine the use of the treatments for acute heart failure (AHF) recommended by ESC guidelines in different clinical presentations and blood pressure groups. METHODS: The use of intravenous diuretics, nitrates, opioids, inotropes, and vasopressors as well as non-invasive ventilation (NIV) was analysed in 620 patients hospitalized due to AHF. The relation between AHF therapies and clinical presentation, especially systolic blood pressure (SBP) on admission, was also assessed. RESULTS: Overall, 76% of patients received i.v. furosemide, 42% nitrates, 29% opioids, 5% inotropes and 7% vasopressors, and 24% of patients were treated with NIV. Furosemide was the most common treatment in all clinical classes and irrespective of SBP on admission. Nitrates were given most often in pulmonary oedema and hypertensive AHF. Overall, only SBP differed significantly between patients with and without the studied treatments. SBP was higher in patients treated with nitrates than in those who were not (156 vs. 141 mmHg, p<0.001). Still, only one-third of patients presenting acute decompensated heart failure and SBP over 120 mmHg were given nitrates. Inotropes and vasopressors were given most frequently in cardiogenic shock and pulmonary oedema, and their use was inversely related to initial SBP (p<0.001). NIV was used only in half of the cardiogenic shock and pulmonary oedema patients. CONCLUSIONS: The management of AHF differs between ESC clinical classes and the use of i.v. vasoactive therapies is related to the initial SBP. However, there seems to be room for improvement in administration of vasodilators and NIV.
AIMS: To examine the use of the treatments for acute heart failure (AHF) recommended by ESC guidelines in different clinical presentations and blood pressure groups. METHODS: The use of intravenous diuretics, nitrates, opioids, inotropes, and vasopressors as well as non-invasive ventilation (NIV) was analysed in 620 patients hospitalized due to AHF. The relation between AHF therapies and clinical presentation, especially systolic blood pressure (SBP) on admission, was also assessed. RESULTS: Overall, 76% of patients received i.v. furosemide, 42% nitrates, 29% opioids, 5% inotropes and 7% vasopressors, and 24% of patients were treated with NIV. Furosemide was the most common treatment in all clinical classes and irrespective of SBP on admission. Nitrates were given most often in pulmonary oedema and hypertensive AHF. Overall, only SBP differed significantly between patients with and without the studied treatments. SBP was higher in patients treated with nitrates than in those who were not (156 vs. 141 mmHg, p<0.001). Still, only one-third of patients presenting acute decompensated heart failure and SBP over 120 mmHg were given nitrates. Inotropes and vasopressors were given most frequently in cardiogenic shock and pulmonary oedema, and their use was inversely related to initial SBP (p<0.001). NIV was used only in half of the cardiogenic shock and pulmonary oedemapatients. CONCLUSIONS: The management of AHF differs between ESC clinical classes and the use of i.v. vasoactive therapies is related to the initial SBP. However, there seems to be room for improvement in administration of vasodilators and NIV.
Authors: JoAnn Lindenfeld; Nancy M Albert; John P Boehmer; Sean P Collins; Justin A Ezekowitz; Michael M Givertz; Stuart D Katz; Marc Klapholz; Debra K Moser; Joseph G Rogers; Randall C Starling; William G Stevenson; W H Wilson Tang; John R Teerlink; Mary N Walsh Journal: J Card Fail Date: 2010-06 Impact factor: 5.712
Authors: John T Parissis; Maria Nikolaou; Alexandre Mebazaa; Ignatios Ikonomidis; Juan Delgado; Fabio Vilas-Boas; Ioannis Paraskevaidis; Antony Mc Lean; Dimitrios Kremastinos; Ferenc Follath Journal: Eur J Heart Fail Date: 2010-09-13 Impact factor: 15.534
Authors: Alexandre Mebazaa; John Parissis; Raphael Porcher; Etienne Gayat; Maria Nikolaou; Fabio Vilas Boas; J F Delgado; Ferenc Follath Journal: Intensive Care Med Date: 2010-11-18 Impact factor: 17.440
Authors: F Follath; M B Yilmaz; J F Delgado; J T Parissis; R Porcher; E Gayat; Nigel Burrows; A McLean; F Vilas-Boas; A Mebazaa Journal: Intensive Care Med Date: 2011-01-06 Impact factor: 17.440
Authors: Veli-Pekka Harjola; Ferenc Follath; Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Matthias Hochadel; Michel Komajda; Jose L Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi Journal: Eur J Heart Fail Date: 2010-03 Impact factor: 15.534
Authors: Sean P Collins; Peter S Pang; Christopher J Lindsell; Demetrios N Kyriacou; Alan B Storrow; Judd E Hollander; J Douglas Kirk; Chadwick D Miller; Richard Nowak; W Frank Peacock; Miguel Tavares; Alexandre Mebazaa; Mihai Gheorghiade Journal: Eur J Heart Fail Date: 2010-08-25 Impact factor: 15.534
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: Wilfried Mullens; Zuheir Abrahams; Gary S Francis; Hadi N Skouri; Randall C Starling; James B Young; David O Taylor; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2008-07-15 Impact factor: 24.094
Authors: Alasdair Gray; Steve Goodacre; David E Newby; Moyra Masson; Fiona Sampson; Jon Nicholl Journal: N Engl J Med Date: 2008-07-10 Impact factor: 91.245
Authors: Veli-Pekka Harjola; Said Laribi; Pia Harjola; Tuukka Tarvasmäki; Cinzia Barletta; Richard Body; Jean Capsec; Michael Christ; Luis Garcia-Castrillo; Adela Golea; Mehmet A Karamercan; Paul-Louis Martin; Òscar Miró; Jukka Tolonen; Oene van Meer; Ari Palomäki; Franck Verschuren Journal: BMC Emerg Med Date: 2022-02-14